Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Specialty Pharma In Transition: Is A U.S. Presence Necessary?

Executive Summary

European-based specialty pharma is at a crossroads. For several of the current generation of Shire PLC hopefuls – companies whose strategy, broadly defined, is focused on late-stage in-licensing and commercialization – 2011 could prove a transformational and, for some, a make-or-break year.

You may also be interested in...

Eyeing Solo U.S. Debut, EU Biotech ThromboGenics Preps Ocriplasmin For Launch

Small European biotechs usually build their business in their home region first, and later look to the US for growth. Belgium's ThromboGenics is doing the opposite; it aims to launch its lead product initially in the US, and will tackle Europe after partner and market leader Alcon paves the way.

With U.S Approval, EUSA Set To Prove Value of Transatlantic Spec Pharma Model – And Orphan Focus

U.S approval of orphan drug Erwinase puts specialty pharma firm EUSA on new growth trajectory, showing the value of its strategy to build a transatlantic infrastructure for niche products – and transitioning it from a commercially-focused to a development-capable organization.

European Spec Pharma Testing New Niches: Emerging Markets, Novel Products

Many struggling European specialty pharma companies are grappling with whether to move outside the traditional business mold by venturing beyond Europe, including into emerging markets, and how to develop differentiated products with potential for transformative growth.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts